Name | Aminopterinum |
Synonyms | AGPA nsc739 Aminopterin AMINOPTERIN 4-AMINO-PGA AMINOPTERINE Aminopterine ai3-26079[qr] Aminopterinum 4-amino-pga[qr] 4-amino-folicaci pteridin-2-amine 4-Aminofolic Acid 4-AMINOFOLIC ACID 4-aminofolicacid[qr] 4-AMINOPTEROYLGLUTAMIC ACID 4-aminopteroylglutamicacid[qr] 4-AMINOPTEROYL-L-GLUTAMIC ACID 4-amino-4-deoxypteroylglutamate 4-diamino-6-pteridinyl)methyl)amino)benzoyl)-n-(p-(((l-glutamicaci N-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)glutamic acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid N-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid (S)-2-{4-[2,4-diaMinopteridin-6yl)MethylaMino]benzoaMido}pentanedioic acid N-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)carbonyl]-D-glutamic acid |
CAS | 54-62-6 |
EINECS | 200-209-9 |
InChI | InChI=1/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/t12-/m1/s1 |
Molecular Formula | C19H20N8O5 |
Molar Mass | 440.41 |
Density | 1.4378 (rough estimate) |
Melting Point | 225 °C |
Boling Point | 551.67°C (rough estimate) |
Specific Rotation(α) | 18 º (c=1% in 0.1N NaOH) |
Flash Point | 87℃ |
Water Solubility | 2 M NaOH: 50 mg/mL |
Solubility | 2 M NaOH: 50mg/mL |
Appearance | powder |
Color | yellow |
Merck | 14,472 |
BRN | 69045 |
pKa | pKa 5.5 (Uncertain) |
Storage Condition | -20°C |
Refractive Index | 1.6910 (estimate) |
MDL | MFCD00150465 |
Use | For the treatment of psoriasis and other skin diseases, can also be used for the treatment of acute and subacute childhood leukemia |
In vitro study | The IC 50 value of Aminopterin (4-Aminofolic acid) against CCRF-CEM cells during 72 h of exposure is 4.4 nM. Aminopterin (4-Aminofolic acid) produces a marked inhibition of mitosis in low concentrations in human leukemic leukocytes. |
Hazard Symbols | T+ - Very toxic |
Risk Codes | R61 - May cause harm to the unborn child R28 - Very Toxic if swallowed R63 - Possible risk of harm to the unborn child R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed. |
Safety Description | S53 - Avoid exposure - obtain special instructions before use. S28 - After contact with skin, wash immediately with plenty of soap-suds. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S22 - Do not breathe dust. |
UN IDs | UN 2811 6.1/PG 1 |
WGK Germany | 3 |
RTECS | MA1050000 |
FLUKA BRAND F CODES | 8-10-23 |
HS Code | 29339900 |
Hazard Class | 6.1(a) |
Packing Group | I |
Toxicity | LDLo orl-rat: 2500 mg/kg JPETAB 95,303,49 |
Reference Show more | 1. Xue Chaojun, Li Qian, Zhi Xuran, etc. Interaction between methotrexate and levetiracetam in rats [J]. Chinese pharmacological Bulletin, 2018, v.34(07):90-97. 2. [IF = 3.932] Ran Fu et al."Wuzhi capsule incremental system exposure to methotrexate by inhibiting the expression of OAT1/3 and P-gp." Ann Transl Med. 2021 May; 9(10): 845 |